Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
Provider: Stock Traders Daily
Provider: New Constructs, LLC
Provider: Sadif Analytics Prime

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

European Commission grants Orphan Drug Designation to Alexion Pharmaceuticals Inc's Soliris

Wednesday, 23 Apr 2014 06:30am EDT 

Alexion Pharmaceuticals Inc:European Commission has granted orphan drug designation (ODD) to Soliris.Soliris is first-in-class terminal complement inhibitor, for prevention of graft rejection following solid organ transplantation. 

Company Quote

-3.455 -1.98%
3:42pm EDT